Abbott has signed a partnership with Velcera to market the first canine pain management product, delivered in a transmucosal mist form.
Currently in clinical trials, the product combines the proven pain medication meloxicam, a nonsteroidal anti-inflammatory drug (NSAID) with Velcera’s patented Promist technology, and has been globally licensed for pain management in dogs.
Under the terms of the agreement, both the parties have committed to consider future product developments and registrations using the Promist technology.
Lynn Bromstedt, divisional vice president at Abbott Animal Health, said: This revolutionary pain management product will be a great addition to Abbott’s existing animal health portfolio and could make medication compliance easier for pet owners.